Literature DB >> 29426752

Increased Dose and Duration of Statin Use Is Associated with Decreased Asthma-Related Emergency Department Visits and Hospitalizations.

Jiu-Yao Wang1, Tsung-Chieh Yao2, Yu-Ting Tsai3, Ann Chen Wu4, Hui-Ju Tsai5.   

Abstract

BACKGROUND: Statins have pleiotropic anti-inflammatory and immunomodulatory effects, yet the effect of statin use on asthma-related emergency department (ED) visits and hospitalizations has remained unclear, especially in Asian populations.
OBJECTIVE: We sought to examine the effect of statin therapy on asthma-related ED visits and/or hospitalizations.
METHODS: A cohort study was conducted using data from Taiwan's National Health Insurance Research Database from 2001 to 2013. A total of 117,595 adult patients with asthma were included. The outcomes were defined as asthma-related ED visits and/or hospitalizations. Multiple Cox proportional hazards models were applied to determine the effect of statin use on asthma-related ED visits and/or hospitalizations.
RESULTS: There were 3,417 asthma-related ED visits and/or hospitalizations among 117,595 subjects with asthma. Statin users were significantly less likely to experience asthma-related ED visits and/or hospitalizations (adjusted hazard ratio: 0.81; 95% confidence interval: 0.74-0.89) compared with nonstatin users. The risks of asthma-related ED visits and/or hospitalizations were decreased among those with a higher cumulative defined daily dose (DDD), greater average DDD, and longer cumulative-day users than the counterparts.
CONCLUSIONS: Our study suggests that statin use is associated with the decreased risk of asthma-related ED visits and/or hospitalizations in patients with asthma. A dose-response effect of statin use is also observed in this study. Therefore, future randomized clinical trials would be warranted to further evaluate the association.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adulthood asthma; Asthma exacerbation; Statin

Mesh:

Substances:

Year:  2018        PMID: 29426752      PMCID: PMC7032037          DOI: 10.1016/j.jaip.2017.12.017

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  31 in total

1.  Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?

Authors:  Amir A Zeki; Jennifer M Bratt; Michelle Rabowsky; Jerold A Last; Nicholas J Kenyon
Journal:  Transl Res       Date:  2010-12       Impact factor: 7.012

Review 2.  Is the prevalence of asthma declining? Systematic review of epidemiological studies.

Authors:  C Anandan; U Nurmatov; O C P van Schayck; A Sheikh
Journal:  Allergy       Date:  2009-11-12       Impact factor: 13.146

3.  The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors.

Authors:  Philippa Ellwood; M Innes Asher; Nils E Billo; Karen Bissell; Chen-Yuan Chiang; Eamon M Ellwood; Asma El-Sony; Luis García-Marcos; Javier Mallol; Guy B Marks; Neil E Pearce; David P Strachan
Journal:  Eur Respir J       Date:  2017-01-11       Impact factor: 16.671

4.  Parent misperception of control in childhood/adolescent asthma: the Room to Breathe survey.

Authors:  W D Carroll; J Wildhaber; P L P Brand
Journal:  Eur Respir J       Date:  2011-06-23       Impact factor: 16.671

5.  Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma.

Authors:  Daniel Menzies; Arun Nair; Karen T Meldrum; Dawn Fleming; Martyn Barnes; Brian J Lipworth
Journal:  J Allergy Clin Immunol       Date:  2006-12-04       Impact factor: 10.793

6.  Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin.

Authors:  Naoya Takeda; Masashi Kondo; Satoru Ito; Yasushi Ito; Kaoru Shimokata; Hiroaki Kume
Journal:  Am J Respir Cell Mol Biol       Date:  2006-07-20       Impact factor: 6.914

7.  The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle.

Authors:  Dedmer Schaafsma; Gordon Dueck; Saeid Ghavami; Andrea Kroeker; Mark M Mutawe; Kristin Hauff; Fred Y Xu; Karol D McNeill; Helmut Unruh; Grant M Hatch; Andrew J Halayko
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-12       Impact factor: 6.914

8.  Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond.

Authors:  Amir A Zeki; Lisa Franzi; Jerold Last; Nicholas J Kenyon
Journal:  Am J Respir Crit Care Med       Date:  2009-07-16       Impact factor: 21.405

9.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

Review 10.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

View more
  9 in total

1.  Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells.

Authors:  Patrick A Paez; Motunrayo Kolawole; Marcela T Taruselli; Siddarth Ajith; Jordan M Dailey; Sydney A Kee; Tamara T Haque; Brian O Barnstein; Jamie Josephine Avila McLeod; Heather L Caslin; Kasalina N Kiwanuka; Yoshihiro Fukuoka; Quang T Le; Lawrence B Schwartz; David B Straus; David A Gewirtz; Rebecca K Martin; John J Ryan
Journal:  J Pharmacol Exp Ther       Date:  2020-05-20       Impact factor: 4.030

Review 2.  Sterols in asthma.

Authors:  Mireia Guerau-de-Arellano; Rodney D Britt
Journal:  Trends Immunol       Date:  2022-08-27       Impact factor: 19.709

3.  PRMT5 in T Cells Drives Th17 Responses, Mixed Granulocytic Inflammation, and Severe Allergic Airway Inflammation.

Authors:  Brandon W Lewis; Stephanie A Amici; Hye-Young Kim; Emily M Shalosky; Aiman Q Khan; Joshua Walum; Kymberly M Gowdy; Joshua A Englert; Ned A Porter; Mitchell H Grayson; Rodney D Britt; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2022-03-14       Impact factor: 5.426

4.  Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database.

Authors:  Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-05-29       Impact factor: 3.535

5.  Statins for asthma.

Authors:  Cho Naing; Han Ni
Journal:  Cochrane Database Syst Rev       Date:  2020-07-15

6.  Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder.

Authors:  Teodor T Postolache; Deborah R Medoff; Clayton H Brown; Li Juan Fang; Sanjaya K Upadhyaya; Christopher A Lowry; Michael Miller; Julie A Kreyenbuhl
Journal:  Pteridines       Date:  2021-09-23       Impact factor: 0.581

7.  Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study.

Authors:  Chin-Wei Kuo; Szu-Chun Yang; Yu-Fen Shih; Xin-Min Liao; Sheng-Hsiang Lin
Journal:  BMC Pulm Med       Date:  2022-03-14       Impact factor: 3.317

Review 8.  Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing.

Authors:  Jason R Burchett; Jordan M Dailey; Sydney A Kee; Destiny T Pryor; Aditya Kotha; Roma A Kankaria; David B Straus; John J Ryan
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

9.  Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data.

Authors:  Rieko Kondo; Shotaro Maeda; Akira Kikuchi; Hiromichi Kiyono; Tohru Sato
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.